EUVIMEDEUVIMED entdecken
LeitlinieKohortenstudie

Population‐Level 10‐Year Implications of the New 2025 American Heart Association/American College of Cardiology Hypertension Guideline Recommendations for Primary Prevention in the United States: A NHANES‐Based Cohort Study (2009–2018)

Mustafa Al-Jarshawi, Sripal Bangalore iD, Harindra C Wijeysundera iD, Nicholas Ws Chew iD, Elad Asher iD, Anastasia S Mihailidou iD, Harriette G C Van Spall iD, Mamas A Mamas iD

Journal of the American Heart Association · 2026

DOI: 10.1161/jaha.125.048616 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Mustafa Al-Jarshawi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Health Informatics, Division of Informatics, Imaging and Data Science, Faculty of Biology, Medicine and Health University of Manchester Ma…. Hauptthemen laut MEDLINE: Hypertension, Antihypertensive Agents, Practice Guidelines as Topic, Primary Prevention. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In August 2025, the American Heart Association and American College of Cardiology released updated hypertension guidelines. Under the new guidelines, therapy is advised at blood pressure ≥130/80 mm Hg in adults with diabetes, chronic kidney disease, or a Predicting Risk of Cardiovascular Disease Events‐estimated 10‐year cardiovascular disease risk ≥7.5%. The long‐term population‐level changes following these guidelines remains uncertain.

Methods

We analyzed NHANES (National Health and Nutrition Examination Survey) 2009 to 2018 data linked to mortality through 2019. Hypertensive adults without baseline cardiovascular disease were included. Treatment eligibility was defined using guideline criteria. Cox models estimated associations between antihypertensive therapy and all‐cause and cardiovascular mortality. Simulation analyses projected lives saved under full and partial treatment uptake.

Results

The weighted cohort represented 81.0 million US adults with hypertension. Of these, 22.8 million (28%) were guideline eligible for therapy; 13.1 million (57%) were treated, and 9.7 million (43%) remained untreated. Antihypertensive therapy was associated with a 23% reduction in all‐cause mortality (hazard ratio [HR], 0.77 [95% CI, 0.63–0.94]) and 50% reduction in cardiovascular mortality (HR, 0.50 [95% CI, 0.36–0.68]). At 10 years, universal treatment of eligible but untreated adults was projected to prevent ~200 900 all‐cause and ~ 162 600 cardiovascular deaths. Benefits were greatest in adults with diabetes.

Conclusions

In this nationally representative cohort, nearly 1 in 3 US adults with hypertension were newly eligible for therapy under the guideline, yet >2 in 5 remained untreated. Extending treatment to all eligible adults could prevent >200 000 all‐cause and 160 000 cardiovascular deaths over the next decade.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionAntihypertensive AgentsPractice Guidelines as TopicPrimary PreventionCardiovascular DiseasesCardiologyHumansUnited StatesAmerican Heart AssociationNutrition SurveysFemaleMiddle AgedMaleAdultAgedTime FactorsRisk FactorsRisk Assessment

Stichwörter der Autor:innen

2025 AHA/ACC guidelinesNHANESPREVENT risk scoreantihypertensive therapycardiovascular mortalityhypertensionprimary prevention

Substanzen

Antihypertensive Agents

Autor:innen und Institutionen

  • Centre for Health Informatics, Division of Informatics, Imaging and Data Science, Faculty of Biology, Medicine and Health University of Manchester Manchester UK.
  • Keele Cardiovascular Research Group, Centre for Prognosis Research Keele University Keele UK.
  • New York University Langone Medical Center New York NY USA.
  • Schulich Heart Centre, Sunnybrook Health Sciences Centre University of Toronto Toronto ON Canada.
  • The Institute for Clinical Evaluative Sciences (ICES) Toronto ON Canada.
  • Temerty Faculty of Medicine University of Toronto Toronto ON Canada.

ORCID-Profile: Sripal Bangalore, Harindra C Wijeysundera, Nicholas Ws Chew, Elad Asher, Anastasia S Mihailidou, Harriette G C Van Spall, Mamas A Mamas

Zitieren

APA

Al-Jarshawi, M., Bangalore, S., Wijeysundera, H. C., Chew, N. W., Asher, E., Mihailidou, A. S., Van Spall, H. G. C., & Mamas, M. A. (2026). Population‐Level 10‐Year Implications of the New 2025 American Heart Association/American College of Cardiology Hypertension Guideline Recommendations for Primary Prevention in the United States: A NHANES‐Based Cohort Study (2009–2018). Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.048616

Vancouver

Al-Jarshawi M, Bangalore S, Wijeysundera HC, Chew NW, Asher E, Mihailidou AS, et al. Population‐Level 10‐Year Implications of the New 2025 American Heart Association/American College of Cardiology Hypertension Guideline Recommendations for Primary Prevention in the United States: A NHANES‐Based Cohort Study (2009–2018). Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.048616

BibTeX
@article{AlJarshawi2026,
  author = {Al-Jarshawi, Mustafa and Bangalore, Sripal and Wijeysundera, Harindra C and Chew, Nicholas Ws and Asher, Elad and Mihailidou, Anastasia S and Van Spall, Harriette G C and Mamas, Mamas A},
  title = {Population‐Level 10‐Year Implications of the New 2025 American Heart Association/American College of Cardiology Hypertension Guideline Recommendations for Primary Prevention in the United States: A NHANES‐Based Cohort Study (2009–2018)},
  journal = {Journal of the American Heart Association},
  year = {2026},
  doi = {10.1161/jaha.125.048616}
}
Kostenlos starten →